PUBLIC COMPANY
save$NRSNNeuroSense Therapeutics Ltd.
$NRSNHerzliya, ILupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
- phase2A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Insider activity
source: SEC Form 4routine RSU / option mechanics (3)
- Mar 26, 26grantEisenberg Or · Chief Financial Officer200,000 sh
- Mar 26, 26grantRussek-Blum Niva · Chief Technology Officer200,000 sh
- Mar 26, 26grantBinder Hagit · General Manager200,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that